Back to dashboard
CommercialCoverageMedium impact

ADHD stimulant-formulary coverage update

Blue Cross Blue Shield of Rhode Island·RI · Family Medicine, Internal Medicine, Pediatrics +2 more·Provider Update
Effective date
Oct 1, 2018
We identified it
Jun 20, 2026
Days to comply

Summary

BCBSRI is removing generic versions of Adderall XR and Concerta from their formulary effective October 1, 2018, making brand versions the preferred option with lower copayments. Members with existing generic authorizations will not be affected.

Action Required

Action needed
By October 1, 2018: Billing team should verify patient formulary status when processing ADHD stimulant prescriptions. Advise providers that brand versions (Adderall XR, Concerta) are now preferred over generics for better patient copayments. Update prior authorization tracking to note existing generic authorizations remain valid.